JHVEPhoto/iStock Editorial via Getty Images
- Merc (New York Stock Exchange: Merck) and its Sichuan partner Kelun-Biotech reported that phase III data on its antibody drug candidate Sacituzumab tirumotecan (sac-TMT) led to a 69% reduction in the risk of progression or death in people with triple-negative breast cancer.
- From 233 Of enrolled individuals, 26% were previously taking PD-1/PD-L1 inhibitors, and 48% had received at least three prior lines of chemotherapy.
- Additional data noted that progression-free survival was 5.7 months with sac-TMT versus 2.3 months with chemotherapy.
- The objective response rate was 43.8% with sac-TMT and 12.8% with chemotherapy.
- The most common grade ≥ 3 treatment-related adverse events (cyst-TMT vs. chemotherapy) were low neutrophil count (32.3% vs. 47%), anemia (27.7% vs. 6.1%), and low white blood cell count (25.4%). % versus 36.4%).
- The results will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2.
